Potential use cases for AML MRD
| • Deep quantification of antileukemia efficacy (eg, log reduction after 2 cycles of therapy) |
| • Early relapse detection and intervention during sequential monitoring |
| • Therapeutic assignment (eg, selection of transplant intensity where otherwise equipoise) |
| • Patient selection for clinical trials (eg, high-risk group of unmet need) |
| • As a surrogate endpoint for overall survival for regulatory approval |
| • Deep quantification of antileukemia efficacy (eg, log reduction after 2 cycles of therapy) |
| • Early relapse detection and intervention during sequential monitoring |
| • Therapeutic assignment (eg, selection of transplant intensity where otherwise equipoise) |
| • Patient selection for clinical trials (eg, high-risk group of unmet need) |
| • As a surrogate endpoint for overall survival for regulatory approval |